New drug shows promise for controlling rare kidney disorders
NCT ID NCT05809531
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep reducing protein in urine, a sign of kidney damage, over a longer period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegcetacoplan
- What this could lead to
- If successful, this could provide a long-term treatment option to control kidney damage in people with C3G or IC-MPGN.
- What could go wrong
- This is an extension study, so it only includes people who already responded well. It may not show benefit for all patients, and long-term risks are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULONEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AMC Apotheek Goederenontvangst (31002)
Amsterdam, 1105 AZ, Netherlands
-
Academic Medical Research Institute (01034)
Los Angeles, California, 90022, United States
-
CHU de Bordeaux - Hopital Pellegrin (33010)
Bordeaux, 33076, France
-
CHUV Lausanne (41002)
Lausanne, CH-1011, Switzerland
-
Catholic University of Leuven (32001)
Leuven, B-3000, Belgium
-
Children's Hospital Colorado (01037)
Aurora, Colorado, 80045, United States
-
Clinica Privada Velez Sarsfield (54007)
Córdoba, X5000, Argentina
-
Cohen Children Hospital, Pediatric Pharmacy (01022)
Hyde Park, New York, 11040, United States
-
Columbia Nephrology (01039)
New York, New York, 10032, United States
-
Emory Investigational Drug Service (01021)
Atlanta, Georgia, 30322, United States
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (39004)
Milan, 20122, Italy
-
HC UNESP Botucatu (55010)
Botucatu, 18618-687, Brazil
-
Hackensack Meridian Health (01036)
Hackensack, New Jersey, 07601, United States
-
Hosp. Universit. Materno-Infantil Vall d' Hebron (34006)
Barcelona, 8035, Spain
-
Hospital De Base (55014)
São José do Rio Preto, 1500900-000, Brazil
-
Hospital Privado-Universitario de Cordoba (54004)
Córdoba, CPA X5016KEH, Argentina
-
Hospital Universitario 12 de Octubre (34008)
Madrid, 28041, Spain
-
Hospital Universitario Dr Peset (34009)
Valencia, 46017, Spain
-
Hospital de Clinicas de Porto Alegre (55018)
Porto Alegre, 90035-903, Brazil
-
Hospital do Rim - Fundacao Oswaldo Ramos (55005)
São Paulo, 04038-002, Brazil
-
Imperial College Hammersmith Hospital (44013)
London, W12 0HS, United Kingdom
-
Institut de transplantation urologie-nephrologie (33011)
Nantes, 44093, France
-
Institute for Clinical and Experimental Medicine (42001)
Prague, 14021, Czechia
-
Irmandade da Santa Casa Misericordia Porto Alegre (55016)
Porto Alegre, Rio Grande do Sul, 90020-090, Brazil
-
Istituto di Ricerche Farmacologiche Mario Negri IRCCS (39003)
Ranica, 24020, Italy
-
Kidney Trials Unit, Princess Alexandra Hospital (61007)
Woolloongab, Queensland, 4102, Australia
-
Nagasaki University Hospital (81005)
Nagasaki, Nagasaki, 852-8501, Japan
-
Northeast Clinical Research Center LLC (01009)
Bethlehem, Pennsylvania, 18017, United States
-
Nottingham University Hospitals NHS Trust (44012)
Nottingham, NG7 2UH, United Kingdom
-
Oregon Health & Science Univ., Dept. Pediatrics (01038)
Portland, Oregon, 97239, United States
-
Ospesale Pediatrico bambino Gesu (39005)
Rome, 165, Italy
-
Radboud University Medical Center (31003)
Nijmegen, 6500 HB, Netherlands
-
Real Hospital Portugues de Beneficencia (55015)
Recife, 52010-095, Brazil
-
Royal Manchester Children's Hospital (44011)
Manchester, M13 9WL, United Kingdom
-
Ruschel Medicina E Pesquisa Clinica (55012)
Rio de Janeiro, 22270-060, Brazil
-
Santa Casa de Misericordia de Belo Horizonte (55017)
Belo Horizonte, Minas Gerais, 30150-221, Brazil
-
Schneider Childrens Medical Center (97204)
Petah Tikva, 4920235, Israel
-
Seirei Hamamatsu General Hospital (81004)
Hamamatsu, Shizuoka, 430-8558, Japan
-
Seoul National University Hospital (82003 & 82005)
Soeul, 3080, South Korea
-
St. Vincent's Hospital Melbourne (61003)
Fitzroy, 3065, Australia
-
Texas Children's Hospital (01027)
Houston, Texas, 77030, United States
-
Univ Sao Paulo, Av. Dr Eneas Carvalho de Aguiar, 155 (55007)
São Paulo, 05403-900, Brazil
-
University Medical Center Groningen (31004)
Groningen de Brug, 9713 GZ, Netherlands
-
University of Florida, Department of Pediatric Nephrology (01010)
Gainsville, Florida, 32610, United States
-
University of Iowa Hospital and Clinics (01030)
Iowa City, Iowa, 52242, United States
-
University of Michigan Hospital (01008)
Ann Arbor, Michigan, 48109, United States
-
Yonsei University College of Medicine, Sinchon Severance Hospital (82002)
Seoul, 3722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted therapy tame rare kidney diseases in daily practice?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- New drug iptacopan studied for rare kidney disease C3G
- New drug aims to stop kidney disease from coming back after transplant
- New drug combo aims to tame rare kidney diseases
- New hope for rare kidney disease: experimental drug NM8074 enters human trials